ethyl (E)-2-phenoxy-4-phenylbut-3-enoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (E)-2-phenoxy-4-phenylbut-3-enoate
• 化学式: C₁₈H₁₈O₃
• 分子量: 282.339
• InChiKey: PNYJRDMTPBNCBH-BUHFOSPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  反-苯乙烯乙酸 在 dirhodium tetraacetate 、 ABSA 、 硫酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 、 苯 为溶剂， 反应 5.5h， 生成 ethyl (E)-2-phenoxy-4-phenylbut-3-enoate
  参考文献：
  名称：

  A Stereospecific Access to Allylic Systems Using Rhodium(II)−Vinyl Carbenoid Insertion into Si−H, O−H, and N−H Bonds

  摘要：

  Rhodium-catalyzed decomposition of alpha-vinyldiazoesters in the presence of silanes, alcohols, ethers, amines, and thiols have been shown to produce the corresponding alpha-silyl, alpha-hydroxy, alpha-alkoxy, alpha-amino, and alpha-thioalkoxy esters in generally good yield with a complete retention of the stereochemistry of the double bond of the diazo precursor. An extension of the process in homochiral series has also been devised using either a chiral auxiliary attached to the ester function or achiral alpha-vinyldiazoesters and Doyle's chiral catalyst Rh-2(MEPY)(4). In the former approach, pantolactone as chiral auxiliary gave diastereoselectivities of up to 70%, while the second approach produced the desired allylsilane with ee as high as 72%. On the other hand, Rh-2(MEPY)(4)-catalyzed insertion into the O-H bond of water led to poor or no enantioselectivity in good agreement with recent literature reports.

  DOI：

  10.1021/jo961952j

文献信息

• Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes
  申请人：Zeiller Jean-Jacques

  公开号：US20100261789A1

  公开（公告）日：2010-10-14

  The present invention relates to butenoic acid derivatives of the formula I: in which R, R 1 , R 2 and R 3 are as defined in the description, and also to processes for the preparation thereof, to pharmaceutical compositions comprising them and to their use for the treatment of dyslipidaemia, atherosclerosis and diabetes.

  本发明涉及公式I的丁烯酸衍生物：其中R、R1、R2和R3如描述中所定义的，并且涉及其制备方法、包含它们的制药组合物以及它们用于治疗血脂异常、动脉硬化和糖尿病的用途。
• US7820847B2
  申请人：——

  公开号：US7820847B2

  公开（公告）日：2010-10-26
• US8247448B2
  申请人：——

  公开号：US8247448B2

  公开（公告）日：2012-08-21